Alembic Pharmaceuticals: Navigating Growth Amidst Pricing Pressures and Strategic Shifts in Q3 FY26

Alembic Pharmaceuticals Limited has reported a quarter of continued momentum, with its Q3 FY26 performance reflecting strategic geographic expansion and focused execution. The company's revenue for the quarter grew by 11% year-over-year, reaching INR 1,876 crores. For the nine-month period ending December 2025, revenue increased by 12% year-on-year to approximately INR 5,500 crores. This growth was broad-based, fueled by volume expansion, new product launches, and increased traction in ex-U.S. markets.

Despite these positive trends, Alembic faced persistent pricing pressures, particularly in its U.S. generics and API businesses. This led to a moderation in gross margin, which stood at 72% for the quarter compared to 74% in the previous year. The company attributed this to changes in product mix and ongoing pricing challenges, which were partially offset by sustained cost efficiency programs within its International Business. EBITDA before R&D expenses and exceptional items demonstrated robust growth, increasing by 20% year-over-year to INR 464 crores for the quarter, representing 25% of revenue. This indicates improved operating leverage and prudent management of discretionary spending.

Segmental Performance and Strategic Initiatives

Alembic's International Generics business was a significant contributor, with sales reaching INR 954 crores in Q3 FY26. The U.S. direct business grew by 7%, while Canada, Australia, and Europe & ROW segments saw substantial increases of 32%, 65%, and 28% respectively. The API segment also reported growth, with total sales reaching INR 263 crores for the quarter. The India Branded Business delivered a 6% year-on-year growth, achieving a revenue of INR 652 crores, with Gynaecology, Ophthalmology, and Animal Healthcare segments showing accelerating performance.

Key Product Launches and R&D Focus

The company's commitment to pipeline development is evident in its R&D investment, which increased by 33% year-over-year to INR 165 crores for the quarter, aligning with its full-year guidance of INR 600-650 crores. Alembic received 7 approvals in the U.S. during the quarter, adding to its cumulative total of 234 ANDA approvals. The company launched 2 approved products in the U.S. in Q3 FY26 and plans another 4 to 5 launches in Q4 FY26. A significant strategic move is the planned launch of 'Pivya', its first branded product in the U.S., in Q4 FY26. Pivya, an oral antibiotic for uncomplicated urinary tract infections in women, marks a strategic shift towards a part-branded business model, expected to scale up prescription share over the next 12 to 18 months, despite an anticipated impact on near-term profitability.

Addressing Challenges and Future Outlook

Management transparently acknowledged the tepid growth in its India business over the past 3-4 years, attributing it partly to a conservative approach to doctor spending. However, they expressed confidence that the India business would align with market growth rates by Q1 of the coming financial year through operational execution. For the U.S. business, the company expects to achieve 10-12% growth for the full year, supported by higher volumes and new launches. Alembic has also executed out-licensing and manufacturing agreements to scale utilization in its new injectable and onco facilities over the next 12 to 18 months.

In a notable disclosure, the company recognized a one-time provision of INR 42 crores towards employee benefits due to changes under the New Labour Code. This provision, while impacting reported PAT, does not affect operating performance or immediate cash flow. Alembic Pharmaceuticals continues to maintain a sharp focus on profitability and operational excellence, aiming to leverage its diversified portfolio and strategic initiatives for sustained growth in a dynamic pharmaceutical landscape.